By Dean Seal
Shares of Lixte Biotechnologies jumped after the company said it will launch a trial to assess whether its drug LB-100 can aid immunotherapy in the treatment of ovarian clear cell carcinoma.
The stock was up 11% at $1.95 in early trading. Shares have fallen 62% since the start of the year.
The Pasadena, Calif.-based biotechnology company said the Phase 1b collaborative clinical trial will assess whether adding LB-100 to GSK's programmed death receptor-1 blocking monoclonal antibody, dostarlimab, can enhance its effectiveness in treating ovarian clear cell carcinoma.
GSK will provide dostarlimab and financial support for the clinical trial.
Write to Dean Seal at firstname.lastname@example.org
(END) Dow Jones Newswires